Health
FDA Launches Bonus Pilot to Tackle Workforce Crisis
The FDA unveils a new retention bonus program aimed at keeping experienced drug reviewers as the agency faces mounting workforce challenges.
Key Takeaways
- FDA offers retention bonuses to senior drug reviewers in critical divisions
- Vacancy rates exceed 15% as private sector salaries double federal pay
- Review timelines for some drug categories already exceed statutory deadlines
- Pilot covers CDER and CBER staff with 3-year commitment requirements
DE
DT Editorial AI··via endpoints.news